NUWEHealthcare · Medical Devices

NUWE Stock Forecast: Nuwellis, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026

$5.68

−1.73% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 31 Oct 2026 — in the weakest quartile.

Market cap

$2.3M

Ticker Nerd rank

15/ 100

Median analyst target

—

Analysts covering

Revenue$2.0M+14.1% y/y

Operating income−$3.2M

Net income−$4.8M

Free cash flow−$3.2M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+1059.2%

+688.9%

YTD

−90.7%

−95.7%

From 52W high

−96.1%

From 52W low

+1675.0%

$147

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

NUWE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nuwellis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026

15/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Issuance

Accruals

Quality

Revisions

Momentum

Volatility

Value

Size (97): Smaller than most of the companies we track.

Value (0): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NUWE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NUWE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

0 Buy1 Hold0 Sell

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
13 Aug 2024	Roth MKM	Reiterates	Buy	$17
29 July 2024	Roth MKM	Initiates	Buy	—
8 Nov 2023	Ladenburg Thalmann	Downgrade	Neutral	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NUWE appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

NUWE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Nuwellis, Inc. returned −95.7% against +12.4% for the S&P 500, dividends included.

NUWE vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NUWE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year

Analysts raising

Analysts cutting

Fundamentals

Nuwellis, Inc. (NUWE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.0×
Price / sales: 0.2×
Price / book: −0.5×
EV / EBITDA: 0.1×

Growth & margins

Revenue growth (YoY): 14.1%
Earnings growth (YoY): 14.1%
Gross margin: 76.1%
Operating margin: −160.9%
Net margin: −125.6%

Returns & dividend

Return on equity: −666.0%
Return on assets: −87.8%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nuwellis, Inc. (NUWE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Nuwellis, Inc. has a market value of $2.3M and an enterprise value of −$1.4M.
Revenue in the twelve months to 30 June 2026: $9.0M. The latest quarter grew 14.1% year on year.
Net income over the same four quarters: −$11.3M, a −125.6% net margin.
Diluted earnings per share, trailing twelve months: $−132.69.
Free cash flow in the twelve months to 30 June 2026: −$12.7M.
Shares outstanding: 364,295.
Trailing P/E: 0.0×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Nuwellis, Inc. employs 38 people — $237K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

NUWE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
NUWENuwellis, Inc.	$2.3M	15
ICCMIceCure Medical Ltd.	$3.0M	42
CODXCo-Diagnostics, Inc.	$3.2M	39
AIDX20/20 Biolabs, Inc.	$2.8M	3
AMIXAutonomix Medical, Inc.	$3.5M	27
POASPhaos Technology Holdings (Cayman) Ltd.	$2.7M	2
XAIRBeyond Air, Inc.	$3.7M	42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nuwellis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NUWE news & analysis

Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology

GlobeNewsWire · 27 Oct 2026positive

Nuwellis announced that the ULTRA-Peds Registry study of Aquadex, involving 91 pediatric patients at seven children's hospitals, was accepted in Pediatric Nephrology. The company intends to use the clinical evidence to support a proposed expansion of Aquadex's indication to patients weighing 5 kg and above.

Why it matters — The study's acceptance provides clinical evidence relevant to Nuwellis's proposed expansion of Aquadex's indicated patient population.

Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian™ Pediatric CRRT System

GlobeNewsWire · 8 Oct 2026positive

Nuwellis said it will convene a Medical & Nursing Advisory Board on November 18–19, 2026, to support continued development of Vivian, its next-generation pediatric CRRT platform. The system is under development for children as small as 2.5 kg and incorporates multiple fluid-management therapies.

Why it matters — The advisory board is part of Nuwellis’s ongoing development work on its pediatric CRRT platform.

Nuwellis to Highlight Advancements in Fluid Management Across Pediatric Care, Critical Care, and Heart Failure at Leading October Medical Conferences

GlobeNewsWire · 1 Oct 2026positive

Nuwellis announced it will participate in four leading medical conferences in October spanning pediatrics, critical care, and heart failure. At these events, the company will engage with clinicians on the challenge of fluid overload and the role of its Aquadex SmartFlow system in providing precise, controlled fluid removal for patients requiring individualized management.

Why it matters — The conference participation offers NUWE watchers insight into how the company is raising awareness of its Aquadex SmartFlow system among clinicians across multiple specialty care settings.

Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity

GlobeNewsWire · 17 Sept 2026positive

Nuwellis reported strong adoption of its Aquadex SmartFlow consoles, with 31 consoles sold year-to-date. Year-to-date console sales have exceeded full-year sales in seven of the past 10 years, placing Nuwellis on pace for one of its strongest years in console placements and meaningfully expanding its recurring revenue opportunity.

Why it matters — A NUWE watcher would care because record-level console placements broaden the installed base that drives recurring revenue.

Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs

GlobeNewsWire · 16 Sept 2026positive

Nuwellis, Inc. announced the appointment of Brian Johnson as Director of Quality and Regulatory Affairs. Johnson brings 13 years of experience in the medical device sector, supporting quality systems, regulatory compliance, audits, and product development.

Why it matters — A dedicated leader with deep quality and regulatory expertise could help Nuwellis manage compliance and support the development of its medical device products.

FAQ

Frequently asked questions about NUWE stock

Is NUWE stock a buy right now?

Of the 1 analysts covering Nuwellis, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nuwellis, Inc. 15 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NUWE?

As at 31 Oct 2026, Nuwellis, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the NUWE stock forecast for 2030?

No analyst covering Nuwellis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NUWE are extrapolating price history, which says nothing about the business.

How has NUWE stock performed over the past year?

Nuwellis, Inc. returned -95.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Nuwellis, Inc. do?

Nuwellis, Inc. is a medical technology company focused on fluid management for patients with cardiorenal and cardiovascular conditions.

What is the latest news on NUWE?

The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology". Nuwellis announced that the ULTRA-Peds Registry study of Aquadex, involving 91 pediatric patients at seven children's hospitals, was accepted in Pediatric Nephrology. The company intends to use the clinical evidence to support a proposed expansion of Aquadex's indication to patients weighing 5 kg and above.

Company

About Nuwellis, Inc.

Nuwellis, Inc. is a medical technology company focused on fluid management for patients with cardiorenal and cardiovascular conditions. The company develops and commercializes ultrafiltration therapy systems, including the Aquadex SmartFlow and Aquadex FlexFlow platforms, which are designed to remove excess fluid when conventional medical management, such as diuretics, is not sufficient. Its devices are used in hospital settings for adult and pediatric patients, supporting clinicians in acute and critical care environments. Nuwellis serves the healthcare market through products intended to address fluid overload, a condition associated with heart failure and related complications. Headquartered in Eden Prairie, Minnesota, Nuwellis concentrates on specialized medical devices that help providers manage complex fluid-balance needs across a range of clinical settings.

CEO Mr. Michael Kendrick McCormick · 38 employees · United States · https://www.nuwellis.com